Skip to content

Handgrip exercise in models of IR

The effect of handgrip exercise on reducing myocardial injury in various ex vivo models of ischemia reperfusion - Handgrip exercise in models of IR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57691
Enrollment
15
Registered
2025-04-09
Start date
2025-07-02
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemia reperfusion injury cardiac damage

Interventions

A single session of local handgrip exercise with an intensity of 50% of their maximal contractile strength.

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Adults >18 years, <65 years. - BMI < 30kg/m2 - Recreational athlete (i.e. minimal 1h/week exercise, maximal 5 days/week of exercise) - Mentally able/allowed to give informed consent

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Presence of an absolute contra-indication for the performance of exercise (see also SOP Inspanningstest Department of Physiology): - Acute myocardial infarction (3-5 days) - Unstable angina - Uncontrolled arrhythmias causing symptoms or hemodynamic compromise - Active endocarditis - Acute myocarditis or pericarditis - Symptomatic severe aortic stenosis - Uncontrolled heart failure - Acute pulmonary embolus or pulmonary infarction - Thrombosis of lower extremities - Suspected dissecting aneurysm - Uncontrolled asthma - Pulmonary oedema - Respiratory failure - Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)- Smoking - Mental impairment leading to inability to cooperate - Use of medication that alters the effect of cardioprotection: • ß-blockers • Calcium Channel blockers • Nitrates • Opioids • Anti-platelet agents (e.g. paracetamol) • Statins and anti-hyperlipidaemic drugs • Anti-diabetic treatment

Design outcomes

Primary

MeasureTime frame
The reduction of myocardial injury via the transfer of humoral cardioprotective agents, present in plasma obtained before/after handgrip exercise in various ex vivo models of IR.

Secondary

MeasureTime frame
Secondary study parameters involve the measurement of cardiac mechanical function, altered cardioprotective signal transduction, histological assessment of tissue integrity, metabolic alterations, and the detection of biomarkers of injury (lactate dehydrogenase).

Countries

Netherlands

Contacts

Public ContactTom Luiken

Radboud Universitair Medisch Centrum

tom.luiken@radboudumc.nl024 3613416

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026